Concurrent alterations of EGFR A289V and EGFR Amplification, IDH1 R132H and PIK3R1 N564D and IDH1 R132H and TP53 R273C have been described previously as signatures of mutation and selection in the cancer genome [39]. This evidence concerns the gene EGFR and cancer.